BGI Genomics Co

BGI Genomics Co Debt/EBITDA

The Total Debt to EBITDA Ratio of BGI Genomics Co (300676.SZ) as of Oct 29, 2026 is -2.61. In the previous year, Total Debt to EBITDA Ratio was -0.60 — a change of 333.60% (lower).

Debt/EBITDA

-2.61

YoY

333.60%

Last updated:

Total Debt to EBITDA Ratio of BGI Genomics Co is 2025 -2.61 . Total Debt to EBITDA Ratio of BGI Genomics Co was 2024 -0.60 . It decreases by 333.60% lower compared to the previous year.

The BGI Genomics Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.06 CNY
Jan 1, 2019
0.73 CNY
Jan 1, 2020
0.53 CNY
Jan 1, 2021
0.38 CNY
Jan 1, 2022
0.11 CNY
Jan 1, 2023
0.96 CNY
Jan 1, 2024
-0.60 CNY
Jan 1, 2025
-2.61 CNY
The BGI Genomics Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-2.61+333.60%
-0.60-162.74%
0.96+754.29%
0.11-70.11%
0.38-28.97%
0.53-27.89%
0.73+1,161.08%
0.06+297.23%
0.01+47.78%
0.01-61.69%
0.03-83.13%
0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BGI Genomics Co Stock analysis

What does BGI Genomics Co do? BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities. BGI Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BGI Genomics Co stock

Total Debt to EBITDA Ratio of BGI Genomics Co is -2.61 in 2025.

Total Debt to EBITDA Ratio of BGI Genomics Co changed from -0.60 to -2.61, representing a 333.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio BGI Genomics Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's BGI Genomics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BGI Genomics Co

All Key Metrics — BGI Genomics Co